Generic inhalation drug developers

75% of current inhaled drug products will go off-patent within the next five years. The market potential is huge. But the challenges are many. The poor quality of data from much conventional preclinical inhalation research technology means many generics companies forget, or are simply unaware of the major benefits, and accelerated drug development, to be gained from non-clinical systems (ex vivo, in vivo, biological and in vitro.) Our nonclinical modules deliver exceptional, strategic data before even entering the costly clinical studies stage.

8 modules for the best strategy at every stage

PreciseInhale’s eight dry powder exposure modules can take you all the way from preclinical to human trials, in one compact system, fast. Eight-module versatility lets you capitalize on synergies. You can cross-validate data and carry out cross-over studies using the same controlled exposure aerosols throughout the research. At each stage our previous data and experience of your priorities supports you in confidently deciding your strategies for the next step.

Generate aerosols from the source of your choice: Inhalers

PreciseInhale is the only inhalation drug development platform that can formulate aerosols from dry powders, nebulized compounds, Dry Powder Inhalers (DPIs) or pressurized Metered Dose Inhalers (pMDIs) with full computer and data monitoring. This generates highly relevant comparative data from marketed products.

In vitro data that is near bioequivalence

European law is sympathetic to the accelerated development of generic inhaled products and values in vitro bioequivalent data highly. Our in vitro module DissolvIt delivers exceptional simulation of absorption and dissolution of respirable particles in the lung epithelium to generic inhalation drug developers, delivering near-bioequivalent data of outstanding quality.

Accelerate drug development with superior data

We deliver critical, high quality ‘go/no go’ data that enables you to make key strategic decisions on continuing or discontinuing projects at an earlier stage of development. Today, many conventional inhalation R&D technologies deliver data with standard deviation >50%.
Our precision dosing and a unique one-animal-at-a-time testing system delivers data with typical standard deviation for an in vivo study of <10%.

Avoid reformulation, speed up drug development

Re-formulating test substances in the middle of trials is costly and time consuming. PreciseInhale generates high-quality aerosols from exceptionally small portions of even challenging dry powders offering a dry powder route from cell studies to clinical trials.

Active dosing delivers even lung distribution

PreciseInhale’s aerosol generator unit removes the powerful energy released during aerosolization from the rodent’s delicate lungs. This delivers finer, more evenly distributed aerosols – and more detailed and accurate data on lung distribution. Our focus on the inhaled dose, measured by computer, avoids the uneven lung distribution, lower quality data and unwanted lung lesions that can occur in conventional technologies where the test powder is released in one focused blast.

Unique regional lung deposition data

Current exposure techniques do not provide regional lung deposition data, developers have to guess when specifying inhaler device technologies. PreciseInhale delivers data not just on the whole lung, but specific regions of it. Regional lung exposure data provides an exceptionally detailed, realistic picture of the true behavior of the inhaled product.